Prestige BioPharma (A950210) Stock Overview
A biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A950210 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Prestige BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,820.00 |
| 52 Week High | ₩20,000.00 |
| 52 Week Low | ₩11,000.00 |
| Beta | 0.98 |
| 1 Month Change | 3.89% |
| 3 Month Change | -11.40% |
| 1 Year Change | -10.72% |
| 3 Year Change | 42.44% |
| 5 Year Change | n/a |
| Change since IPO | -60.91% |
Recent News & Updates
Shareholder Returns
| A950210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.1% | -2.1% | 2.2% |
| 1Y | -10.7% | 46.6% | 65.7% |
Return vs Industry: A950210 underperformed the KR Biotechs industry which returned 47.4% over the past year.
Return vs Market: A950210 underperformed the KR Market which returned 67.7% over the past year.
Price Volatility
| A950210 volatility | |
|---|---|
| A950210 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A950210 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A950210's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 54 | So-Yeon Park | www.prestigebiopharma.com |
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.
Prestige BioPharma Limited Fundamentals Summary
| A950210 fundamental statistics | |
|---|---|
| Market cap | ₩154.09b |
| Earnings (TTM) | ₩15.76b |
| Revenue (TTM) | ₩14.41b |
Is A950210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950210 income statement (TTM) | |
|---|---|
| Revenue | ₩14.41b |
| Cost of Revenue | ₩23.54b |
| Gross Profit | -₩9.13b |
| Other Expenses | -₩24.88b |
| Earnings | ₩15.76b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.31k |
| Gross Margin | -63.32% |
| Net Profit Margin | 109.33% |
| Debt/Equity Ratio | 25.1% |
How did A950210 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 00:16 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prestige BioPharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Junghyun Kim | Kyobo Securities Co., Ltd |
| Keunhee Seo | Samsung Securities Co. Ltd. |